If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
349
results.
Updated on
14/09/2026 [08:02:00]
Results 175 to 200 of 349
Absstract of: WO2018094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsaturated fatty acid ester, an isotopicaliy-modified polyunsaturated fatty acid thioester, an isotopicaliy-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopicaliy-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopicaliy-modified polyunsaturated fatty acid and an oxylipin.
Absstract of: EP4790416A2
The present invention relates to a method comprising the step detecting in a sample an antibody binding specifically to NECAB1, an antibody binding specifically to NECAB1, a carrier such as a diagnostically useful carrier with a solid phase with an immobilized polypeptide comprising an antigen or at least one epitope thereof or a variant of the antigen or epitope thereof, wherein the antigen is NECAB1, and a use of the antibody for diagnosing an autoimmune disease or a cancer.
Absstract of: WO2025106313A1
The present disclosure is related to compositions and methods for analyzing IgG antibody activity or activation of Fcγ receptors by certain antibodies. Also disclosed are transformed cells expressing human Fcγ receptors useful in methods for analyzing IgG antibody bioactivity.
Absstract of: CN122541562A
本申请涉及一种特异性识别磷酸化Tau217蛋白的单克隆抗体、其制备方法，以及包含该抗体的磷酸化Tau217蛋白检测试剂盒，该抗体可用于阿尔茨海默病的早期辅助诊断、病程监测及疗效评估。本发明试剂盒空白限为0.51 pg/mL，检出限为1.04 pg/mL，定量限为3.93 pg/mL，线性范围0.5‑100 pg/mL（线性相关系数r≥0.99），批内精密度CV≤8%，批间精密度CV≤15%，抗干扰性良好，试剂盒稳定性为12个月，开瓶后机载稳定期30天，与进口参比试剂盒相关性良好。
Absstract of: WO2025249975A1
The present invention relates to a novel compound for detecting amyloid-beta and a method for diagnosing degenerative brain disease using same, the compound represented by chemical formula 1 or a salt thereof, according to the present invention, being capable of specifically binding to amyloid-beta. The compound or a salt thereof has high selectivity and thus may detect amyloid-beta in plasma with high sensitivity despite interference in the detection due to the presence of other proteins in plasma, and may be utilized for diagnosing degenerative brain disease or screening a therapeutic agent for degenerative brain disease.
Absstract of: WO2025017127A1
Gp130 antigen-binding antibodies are disclosed which inhibit IL-6, IL-11, OSM, LIF, CNTF, CT-1 mediated signal and bind to the cytokine binding region. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, humanised antibodies and therapeutic methods using, the Gp130 antigen-binding antibodies.
Absstract of: WO2025026908A1
The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.
Absstract of: WO2024192404A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Absstract of: CN122525111A
0001 本发明公开了一种血浆TRAIL水平检测在阿尔茨海默病检测中的应用，涉及生物医学检测技术领域；一种检测人血浆中肿瘤坏死因子相关凋亡诱导配体浓度的物质在制备用于辅助评估受试者阿尔茨海默病相关认知状态的试剂中的应用；所述应用包括：将受试者的血浆TRAIL浓度检测值与预设的参考值范围或诊断阈值进行比较，其中，当所述血浆TRAIL浓度高于用于区分AD与认知功能正常状态的第一诊断阈值时，为辅助判断所述受试者更可能处于AD状态而非CU状态提供信息。本发明基于血浆样本进行检测，仅需常规静脉采血，避免了腰椎穿刺的侵入性风险和PET成像的放射性暴露及高额费用。所使用的酶联免疫吸附测定等技术成熟、操作相对标准化。
Absstract of: CN122525107A
0001 本发明涉及生物标志物技术领域，尤其涉及C1酯酶抑制剂的岩藻糖含量检测试剂在制备2型遗传性血管水肿诊断产品中的应用。本发明发现C1酯酶抑制剂的岩藻糖基化水平与2型遗传性血管水肿具有显著相关性，可用于诊断2型遗传性血管水肿；经ROC曲线验证，C1酯酶抑制剂的岩藻糖基化水平对于2型遗传性血管水肿具有较好的诊断性能，且具有检测方便、所需时间短等优势，可单独或与其他标志物组合用于2型遗传性血管水肿诊断，在2型遗传性血管水肿诊断中具有较好的应用前景。
Absstract of: CN122525140A
0001 本发明涉及生物标志物组合在制备用于APOE ε3/ε3基因型个体阿尔茨海默病的检测试剂盒中的应用，所述的生物标志物选自ANGPTL1，PON2，PTN，SCGB3A1，PBLD，MORC3，EIF5A，FAM3D，PIKFYVE，CKB，HGF，TREH，GSTA3，EIF2AK3，CTSD，FOLH1中的至少一种，实现了在该人群中对阿尔茨海默病高精度、高特异性的体外诊断。
Absstract of: CN122520771A
0001 本发明公开了一种抗β‑淀粉样前体蛋白的抗体及其相关产品和应用，所述抗体可特异性结合β‑淀粉样前体蛋白，具有高亲和力和特异性，所述相关产品包括包含所述抗体的检测试剂盒、检测试剂，可用于β‑淀粉样前体蛋白的检测或β‑淀粉样前体蛋白相关疾病（如：阿尔茨海默病、轻度认知障碍、淀粉样变性相关神经退行性疾病）的诊断或辅助诊断，为临床诊疗提供可靠的分子检测依据。
Absstract of: CN122525131A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau217蛋白测定试剂盒及应用，本申请所述的磷酸化Tau217蛋白测定试剂盒包括特定的抗试剂A、抗试剂B和磁微粒试剂，所述的生物素标记的p‑Tau 217抗体与碱性磷酸酶标记的p‑Tau 217抗体反应生成，抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的特异性结合反应结合到磁性微粒上，能够有效的降低检测限，实现了磷酸化Tau217蛋白的高灵敏度检测，空白限不高于0.20pg/mL，且在0.50pg/mL~50.00pg/mL范围内线性相关性好（r≥0.9900），可实现磷酸化Tau217蛋白的准确定量。
Absstract of: US20260227408A1
0000 The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.
Absstract of: WO2026161967A1
A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.
Absstract of: WO2021039644A1
The present invention addresses the problem of providing a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide in a brain. The present invention relates to a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide included in a cerebrospinal fluid, the method comprising: a step for adding an internal standard substance to a solution containing the cerebrospinal fluid; a step for subjecting the solution, which contains the cerebrospinal fluid and to which the internal standard substance is added, to liquid chromatography to obtain an effluent; and a step for providing the effluent for mass spectrometry.
Absstract of: WO2020146652A1
The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.
Absstract of: US20260226143A1
0000 Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
Absstract of: US20260227396A1
0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Absstract of: US20260227416A1
0000 The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.
Absstract of: US20260226658A1
0000 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Absstract of: US20260224626A1
0000 The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient following treatment of the patient with an immunotherapy product, and methods for improving efficacy of an immunotherapy product for a patient with a likelihood of a relapse to a cancer following treatment with an immunotherapy product.
Absstract of: US20260226177A1
0000 The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson's disease, and others.
Absstract of: WO2026163093A1
Two proteins, Elastase 3B and igKappa chain, are identified as biomarkers for the diagnosis and prognosis of Alzheimer's disease (Alzheimer Disease, AD). These proteins can be detected in fecal samples from subjects affected by this pathology and exhibit a statistically significant variation in samples from AD subjects compared with the levels detected in a healthy reference sample, thereby making it possible to provide both diagnosis and prognosis of AD in a simple and non-invasive manner, in particular, Elastase 3B and igKappa chain emerge as complementary biomarkers with opposite and progressive modulation. Specifically, Elastase 3B decreases in all phases of the pathology, whereas igKappa chain shows a progressive increase that reflects the progression of AD. The combined use of these two proteins as complementary biomarkers is therefore applicable for the early diagnosis and prognosis of AD. To achieve this objective, a strategy based on the use of a preclinical model was adopted, namely the triple-transgenic murine model (3xTg-AD), which mimics the AD pathology observed in humans and reproduces its characteristics and different stages. Based on the premise that the results obtained may also be predictive for humans, the use > of the murine model offers an important advantage, namely the possibility of collecting samples to be analyzed at precise time points, thereby allowing the study of the pathology in its different stages, from the asymptomatic phase to the early sym
Nº publicación: WO2026165150A2 06/08/2026
Applicant:
SIEMENS HEALTHCARE DIAGNOSTICS INC [US]
SIEMENS HEALTHCARE DIAGNOSTICS INC.
Absstract of: WO2026165150A2
Disclosed herein are methods pertaining to analyzing a biological sample from a subject for a neurodegenerative disease. In one aspect, the disclosure relates to a method for analyzing a biological sample from a subject for a neurodegenerative disease. This method involves determining a ratio of pTau217 to BD-Tau present in a biological sample obtained from a subject and diagnosing the subject as (i) having Alzheimer's disease when the ratio of pTau217 to BD-Tau in the sample is a at least a first predetermined value; (ii) a healthy subject (no neurodegenerative disease) when the ratio of pTau217 to BD-Tau in the sample is below a second predetermined value; and/or (iii) having a disease other than Alzheimer's disease associated with high levels of pTau217 when the ratio of pTau217 to BD-Tau in the sample is between the second predetermined value and the first predetermined value.
BOPI
Electronic site
